Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts
AssigneeEmpirico Inc.
InventorsOmri Gottesman, Shannon Bruse, Brian Cajes, David Lewis, David Rozema
Life of this patent
Estimating the term…
Abstract
Provided are compositions comprising an oligonucleotide that targets Thymic stromal lymphopoietin (TSLP). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating an airway disorder by providing an oligonucleotide that targets TSLP to a subject in need thereof. In some embodiments, the oligonucleotide targeting is specific for a long isoform of TSLP (1fTSLP).
Claims15
A composition comprising an oligonucleotide that targets a long isoform of Thymic stromal lymphopoietin (1fTSLP), wherein the oligonucleotide comprises a small interfering RNA (siRNA) comprising a sense strand and an antisense strand;
- and wherein the sense strand comprises the nucleoside sequence of any one of SEQ ID NOs:
- 15048, 15114, 15194, 15252 or 15272, or a nucleic acid sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions.
A method of treating an airway inflammation disorder in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising an siRNA that targets 1fTSLP, comprising a sense strand and an antisense strand;
- and wherein the sense strand comprises the nucleoside sequence of any one of SEQ ID NOs:
- 15048, 15114, 15194, 15252 or 15272, or a nucleic acid sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions.
Dependencies are inferred from the claim text.